IKT INHIBIKASE THERAPEUTICS
Health Care · Russell 2000
Next earnings: Fri 13 Nov 2026 · estimated
What 12 analyst firms say about INHIBIKASE THERAPEUTICS: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
11 rated views · 12 analyst/firm records · 12 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Price below 5 USD
- Russell 2000 · Safest consensus · 6MNot scored · Price below 5 USD
Recent analyst activity · last 90 days
Our tracked history has 2 reports on IKT from 2 analyst firms in the last 90 days (12 firms in the past year).
Comparing each firm's latest target with its previous one: 1 has its first observed target in the past year.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Bank of America Securities | Jason Zemansky | Buy | 21 Jan 2026 | 6.00 USD |
| Cantor Fitzgerald | Olivia Brayer | Buy | 19 May 2026 | 4.00 USD |
| Chardan Capital Markets | Andreas Argyrides | Hold | 13 Oct 2026 | 1.50 USD |
| Freedom Capital Markets | Ilya Zubkov | Buy | 1 Jul 2026 | 3.00 USD |
| H.C. Wainwright | Raghuram Selvaraju | Buy | 31 Jul 2026 | 8.00 USD |
| Jefferies | Dennis Ding | Buy | 1 Jul 2026 | 8.00 USD |
| Ladenburg Thalmann | Caroline Palomeque | Buy | 13 Jul 2026 | 7.00 USD |
| Lifesci Capital | Gaurav Maini | Buy | 23 Feb 2026 | 5.00 USD |
| Maxim Group | Jason Mccarthy | Buy | 15 Mar 2026 | 8.00 USD |
| Oppenheimer | Unnamed analyst | Buy | 10 Jun 2026 | 5.00 USD |
| Weiss Ratings | Unnamed analyst | — | 15 Oct 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 15 Jul 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 03:37 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.